The safety profile of CAR T-cell treatment for highly inflammatory, CNS-targeted autoimmune disorders like relapsing MS is still unclear while it is well established for several effective mAbs approved for MS or AQP4-positive NMOSD. This evidence concerns the gene AQP4 and autoimmune disease.